Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sensei Biotherapeutics ( (SNSE) ) just unveiled an update.
On April 10, 2026, Sensei Biotherapeutics disclosed that three directors tendered conditional resignations effective two business days after the June 10, 2026 annual meeting, contingent on stockholder approval of proposals that would permit conversion of Series B preferred stock into common shares resulting in a change of control and a large increase in authorized common stock. The board simultaneously approved conditional appointments of three new directors, mapped out revised committee memberships, and signaled planned promotions of Anand Parikh to chief executive officer and Brian Stephenson to chief financial officer if the proposals pass, while also adopting a severance and change-in-control plan that provides tiered cash, benefits, and equity acceleration protections for key executives in connection with qualifying terminations, particularly around any change in control.
The most recent analyst rating on (SNSE) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Sensei Biotherapeutics stock, see the SNSE Stock Forecast page.
Spark’s Take on SNSE Stock
According to Spark, TipRanks’ AI Analyst, SNSE is a Neutral.
The score is held down primarily by weak financial performance (no revenue, ongoing losses and cash burn, and a shrinking equity/asset base despite modest leverage). Technicals are mixed but somewhat supportive longer-term, while valuation remains challenging due to negative earnings. Corporate events provide some offset via added capital and pipeline expansion, tempered by meaningful dilution and control structure changes.
To see Spark’s full report on SNSE stock, click here.
More about Sensei Biotherapeutics
Sensei Biotherapeutics, Inc. is a biotechnology company focused on developing immunotherapies, operating under Nasdaq listing rules and governed by a board and committee structure typical of U.S. public biopharma issuers. The company’s leadership and governance framework, including its audit, compensation, and nominating committees, plays a central role in overseeing strategy, capital structure decisions, and executive management changes that can affect its control and capitalization profile.
Average Trading Volume: 313,415
Technical Sentiment Signal: Buy
Current Market Cap: $39.15M
Learn more about SNSE stock on TipRanks’ Stock Analysis page.